Precision Peptide Secures Exclusive Manufacturing Rights for Four Peptide Patches

• The Precision Peptide Company secured exclusive manufacturing rights for all four transdermal peptide formulations through a single U.S. manufacturer.
• TA1 production covers 20,000 patches ordered in October 2026 at 2 mg each, with delivery expected in January 2027.
• BPC-157 patches are on sale following receipt of approximately 20,000 units in July 2026.
• Independent U.S. laboratory testing recorded BPC-157 purity of 95.5%, with a 2.02 mg dose per patch.
• Tirzepatide remains in development following its August 2026 announcement; GLP3 development was announced October 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610220700NEWSFILECNPR____20261022_320328_1) on October 22, 2026, and is solely responsible for the information contained therein.